Business
Alligator Announces Publication in Cancer Immunology Research of Preclinical Data on ATOR-4066, a Tumor-Directed CD40×CEACAM5 Bispecific Antibody
LUND, SE / ACCESS Newswire / September 10, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced the publication of a peer-reviewed article ...
About this update from Alligator Bioscience Ab
[{"type":"text","content":"LUND, SE / ACCESS Newswire / September 10, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced the publication of a peer-reviewed article in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR). The paper presents preclinical data on ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5 developed using Alligator's proprietary Neo-X-Prime™ platform and RUBY™ format.","length":532,"tagName":"p"},{"type":"text","content":"The study, titled "ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEACAM5, induces strong myeloid and T cell dependent tumor immunity and synergizes with PD-1 blockade", highlights the potential of ATOR-4066 to overcome key resistance mechanisms in the tumor microenvironment. The data demonstrates that ATOR-4066 induces localized activation of myeloid cells and T cells within the tumor, while sparing healthy peripheral tissues, resulting in potent antitumor immunity.","length":498,"tagName":"p"},{"type":"text","content":"Key findings from the publication include:","length":42,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Tumor-localized activation: ATOR-4066 selectively activated CD40 in human tumor samples.","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"Potential to outperform other tumor targeting therapies: ATOR-4066 mediates strong anti-tumor activity also in tumors with heterogenous CEACAM5 expression.","length":155,"tagName":"p"}]},{"val":[{"type":"text","content":"Turning the tumor hot: Mechanistic analyses shows that ATOR-4066 efficiently activates the immune system in the tumor resulting in tumor rejection.","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"Synergy with checkpoint blockade: ATOR-4066 demonstrated synergistic activity with anti-PD-1 treatment.","length":103,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":493,"olType":false},{"type":"text","content":""Publication of these data in Cancer Immunology Research underscores the potential of our Neo-X-Prime platform and RUBY format to generate bispecific antibodies capable of reshaping the tumor microenvironment and driving durable immune responses," said Søren Bregenholt, CEO o...